EGFR and chronic kidney disease: In this present study, we demonstrated that the association between losartan, a well-known AT1R antagonist, with erlotinib, a blocker of EGFR activity, successfully provided functional and histomorphological benefits in a CKD model (5/6 nephrectomy) aggravated by VDD.